EUVIMEDEUVIMED entdecken
Übersichtsarbeit

First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel–Lindau disease to advanced renal cell carcinoma

Irem Karaman, Dilek Erdem, Bulent Cetin

Cancer Chemotherapy and Pharmacology · 2026

DOI: 10.1007/s00280-025-04861-x ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2026. Verfasst von Irem Karaman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Basic Helix-Loop-Helix Proteins, Kidney Neoplasms, von Hippel-Lindau Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoxia signaling governs angiogenesis, erythropoiesis, and cellular metabolism; its dysregulation via stabilized hypoxia-inducible factors (HIFs) is a shared driver across cancers. In genitourinary oncology, loss of VHL hardwires HIF-2α activity in clear-cell renal cell carcinoma (ccRCC) and across the VHL tumor spectrum. Belzutifan, which blocks HIF-2α-ARNT dimerization, is the first approved transcription-factor inhibitor in a solid tumor and the first medical therapy for a hereditary kidney-cancer syndrome (VHL). This review consolidates 2023-2025 advances: phase III validation in post-IO/TKI ccRCC (progression-free survival and response-rate gains vs. everolimus), durable first-line activity with cabozantinib, and approval for advanced pheochromocytoma/paraganglioma-including patients ≥ 12 years-extending impact to endocrine and pediatric oncology. We provide GU-focused care pathways (operate vs. treat vs. observe), pragmatic placement of belzutifan in RCC lines of therapy, and standardized monitoring for on-target anemia and hypoxia that requires coordinated oncology-hematology-pulmonology management, alongside contraception and drug-interaction counseling. Future priorities include biomarker-guided selection (HIF-2 signatures, EPAS1 variants), optimal sequencing with immunotherapy and VEGF TKIs, evaluation of triplet and peri-operative/adjuvant strategies, and development of next-generation HIF-2 inhibitors to address resistance; exploration of HIF-1 targeting and non-oncology applications (e.g., pulmonary vascular disease) is warranted. Caution is appropriate: overall survival benefit in randomized RCC trials is not yet demonstrated, resistance can emerge, and long-term hematologic and pulmonary effects require surveillance. Together, HIF-2α inhibition establishes a new, clinically actionable axis in GU oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellBasic Helix-Loop-Helix ProteinsKidney Neoplasmsvon Hippel-Lindau DiseaseAntineoplastic AgentsHumansEndothelial PAS Domain-Containing Protein 1Indenes

Stichwörter der Autor:innen

BelzutifanHypoxia-Inducible factor 2Renal cell carcinomaVon Hippel–Lindau

Substanzen

Endothelial PAS Domain-Containing Protein 1Basic Helix-Loop-Helix ProteinsbelzutifanAntineoplastic AgentsIndenes

Autor:innen und Institutionen

  • Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Department of Medicine, Division of Medical Oncology, VM Medical Park, Samsun, Turkey.
  • Department of Medicine, Division of Medical Oncology, Istinye University Faculty of Medicine, Istanbul, Turkey.
  • Department of Medicine, Division of Medical Oncology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey. caretta06@hotmail.com.

Zitieren

APA

Karaman, I., Erdem, D., & Cetin, B. (2026). First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel–Lindau disease to advanced renal cell carcinoma. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04861-x

Vancouver

Karaman I, Erdem D, Cetin B. First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel–Lindau disease to advanced renal cell carcinoma. Cancer Chemotherapy and Pharmacology. 2026. doi:10.1007/s00280-025-04861-x

BibTeX
@article{Karaman2026,
  author = {Karaman, Irem and Erdem, Dilek and Cetin, Bulent},
  title = {First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel–Lindau disease to advanced renal cell carcinoma},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  doi = {10.1007/s00280-025-04861-x}
}
Kostenlos starten →